Non-Coding Rnas and Glioma: Focus on Cancer Stem Cells Publisher



Rajabi A^{1, 2} ; Kayedi M³ ; Rahimi S⁴ ; Dashti F^{1, 2} ; Mirazimi SMA^{1, 2} ; Homayoonfal M⁵ ; Mahdian SMA⁶ ; Hamblin MR⁷ ; Tamtaji OR^{8, 9} ; Afrasiabi A¹⁰ ; Jafari A^{11, 12} ; Mirzaei H⁵ Show Affiliations
Source: Molecular Therapy Oncolytics Published:2022

Abstract

Glioblastoma and gliomas can have a wide range of histopathologic subtypes. These heterogeneous histologic phenotypes originate from tumor cells with the distinct functions of tumorigenesis and self-renewal, called glioma stem cells (GSCs). GSCs are characterized based on multi-layered epigenetic mechanisms, which control the expression of many genes. This epigenetic regulatory mechanism is often based on functional non-coding RNAs (ncRNAs). ncRNAs have become increasingly important in the pathogenesis of human cancer and work as oncogenes or tumor suppressors to regulate carcinogenesis and progression. These RNAs by being involved in chromatin remodeling and modification, transcriptional regulation, and alternative splicing of pre-mRNA, as well as mRNA stability and protein translation, play a key role in tumor development and progression. Numerous studies have been performed to try to understand the dysregulation pattern of these ncRNAs in tumors and cancer stem cells (CSCs), which show robust differentiation and self-regeneration capacity. This review provides recent findings on the role of ncRNAs in glioma development and progression, particularly their effects on CSCs, thus accelerating the clinical implementation of ncRNAs as promising tumor biomarkers and therapeutic targets. © 2022 The Authors